Drug intelligence / Profile preview

SST002

Development stage: Preclinical
Lead developer: SynuSight Biotech
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

SST002 (also known as SST-002) is an investigational positron emission tomography (PET) tracer and diagnostic imaging agent under development by SynuSight Biotech. It is designed as a radionuclide imaging agent to detect and monitor pathological changes associated with neurodegenerative diseases. Currently in the early discovery and preclinical stages, the specific biological target and primary clinical indications for SST002 remain undisclosed by the developer.

Beyond the preview

Go deeper on SST002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SST002.

Explore the full profile